'Game-changer' cancer treatment is focus of Gilead's $12 billion cell therapy deal

Gilead Sciences' $12 billion investment in cell therapy — announced Monday in its acquisition of Kite Pharma — is a promising step toward advancing the development and commercial viability of a game-changing cancer treatment, biotech analysts and ... #cancertreatment